Literature DB >> 26667070

Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease.

Joel T Haas1,2,3,4, Sven Francque5,6, Bart Staels1,2,3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders characterized by abnormal hepatic fat accumulation, inflammation, and hepatocyte dysfunction. Importantly, it is also closely linked to obesity and the metabolic syndrome. NAFLD predisposes susceptible individuals to cirrhosis, hepatocellular carcinoma, and cardiovascular disease. Although the precise signals remain poorly understood, NAFLD pathogenesis likely involves actions of the different hepatic cell types and multiple extrahepatic signals. The complexity of this disease has been a major impediment to the development of appropriate metrics of its progression and effective therapies. Recent clinical data place increasing importance on identifying fibrosis, as it is a strong indicator of hepatic disease-related mortality. Preclinical modeling of the fibrotic process remains challenging, particularly in the contexts of obesity and the metabolic syndrome. Future studies are needed to define the molecular pathways determining the natural progression of NAFLD, including key determinants of fibrosis and disease-related outcomes. This review covers the evolving concepts of NAFLD from both human and animal studies. We discuss recent clinical and diagnostic methods assessing NAFLD diagnosis, progression, and outcomes; compare the features of genetic and dietary animal models of NAFLD; and highlight pharmacological approaches for disease treatment.

Entities:  

Keywords:  cardiovascular disease; fibrosis; hepatocellular carcinoma; metabolic syndrome; obesity

Mesh:

Year:  2015        PMID: 26667070     DOI: 10.1146/annurev-physiol-021115-105331

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  125 in total

1.  Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults.

Authors:  T Filardi; F Panimolle; C Tiberti; C Crescioli; A Lenzi; N Pallotta; S Morano
Journal:  J Endocrinol Invest       Date:  2020-04-30       Impact factor: 4.256

2.  High-Affinity Low-Capacity and Low-Affinity High-Capacity N-Acetyl-2-Aminofluorene (AAF) Macromolecular Binding Sites Are Revealed During the Growth Cycle of Adult Rat Hepatocytes in Primary Culture.

Authors:  Katherine S Koch; Tom Moran; W Thomas Shier; Hyam L Leffert
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

3.  Leaves of Lippia triphylla improve hepatic lipid metabolism via activating AMPK to regulate lipid synthesis and degradation.

Authors:  Yi Zhang; Mengyang Liu; Qian Chen; Tingting Wang; Haiyang Yu; Jingqi Xu; Tao Wang
Journal:  J Nat Med       Date:  2019-05-18       Impact factor: 2.343

4.  Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob/ob mice.

Authors:  Mei Zhang; Zhi-Fu Xie; Run-Tao Zhang; Da-Kai Chen; Min Gu; Shi-Chao Cui; Yang-Ming Zhang; Xin-Wen Zhang; Yan-Yan Yu; Jia Li; Fa-Jun Nan; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

5.  Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.

Authors:  Jason S Seidman; Ty D Troutman; Mashito Sakai; Anita Gola; Nathanael J Spann; Hunter Bennett; Cassi M Bruni; Zhengyu Ouyang; Rick Z Li; Xiaoli Sun; BaoChau T Vu; Martina P Pasillas; Kaori M Ego; David Gosselin; Verena M Link; Ling-Wa Chong; Ronald M Evans; Bonne M Thompson; Jeffrey G McDonald; Mojgan Hosseini; Joseph L Witztum; Ronald N Germain; Christopher K Glass
Journal:  Immunity       Date:  2020-05-01       Impact factor: 31.745

6.  Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution.

Authors:  Joel T Haas; Luisa Vonghia; Denis A Mogilenko; An Verrijken; Olivier Molendi-Coste; Sébastien Fleury; Audrey Deprince; Artemii Nikitin; Eloïse Woitrain; Lucie Ducrocq-Geoffroy; Samuel Pic; Bruno Derudas; Hélène Dehondt; Céline Gheeraert; Luc Van Gaal; Ann Driessen; Philippe Lefebvre; Bart Staels; Sven Francque; David Dombrowicz
Journal:  Nat Metab       Date:  2019-06-14

7.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.

Authors:  Yan-Xiao Ji; Zan Huang; Xia Yang; Xiaozhan Wang; Ling-Ping Zhao; Pi-Xiao Wang; Xiao-Jing Zhang; Michele Alves-Bezerra; Lin Cai; Peng Zhang; Yue-Xin Lu; Lan Bai; Mao-Mao Gao; Huan Zhao; Song Tian; Yong Wang; Zhi-Xiang Huang; Xue-Yong Zhu; Yan Zhang; Jun Gong; Zhi-Gang She; Feng Li; David E Cohen; Hongliang Li
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

8.  Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Authors:  Magar Ghazarian; Xavier S Revelo; Mark K Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D'Angelo; Peter Horton; William C Chapman; Diane Brockmeier; Minna Woo; Edgar G Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J Gehring; Shawn Winer; Daniel A Winer
Journal:  Sci Immunol       Date:  2017-04-21

Review 9.  Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease.

Authors:  Anand R Saran; Shravan Dave; Amir Zarrinpar
Journal:  Gastroenterology       Date:  2020-02-13       Impact factor: 22.682

Review 10.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.